Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Scancell Hldgs Plc

Healthcare GB SCLP

22.5GBX
-0.5(2.17%)

Last update at 2026-06-04T15:35:00Z

Day Range

22.5023.50
LowHigh

52 Week Range

7.8614.00
LowHigh

Fundamentals

  • Previous Close 23.00
  • Market Cap127.13M
  • Volume378333
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.96300M
  • Revenue TTM4.71M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 4.47M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Income before tax -15.30300M -9.11700M -14.30400M -3.76800M -16.80500M
Minority interest - - - - -
Net income -12.27200M -5.85900M -11.93600M -2.06500M -15.47700M
Selling general administrative 4.79M 5.40M 5.02M 4.79M 3.35M
Selling and marketing expenses - - - - -
Gross profit 3.59M -0.96600M 4.75M - -
Reconciled depreciation 0.88M 0.97M 0.90M 0.74M 0.25M
Ebit -13.58600M -8.02800M -11.63600M -13.29900M -8.83400M
Ebitda -12.70700M -7.06200M -10.73400M -7.31200M -14.90500M
Depreciation and amortization 0.88M 0.97M 0.90M 5.99M -6.07100M
Non operating income net other - - - - -
Operating income -15.00100M -18.26700M -11.92000M -13.29900M -8.83400M
Other operating expenses 19.71M 18.27M 17.19M 13.30M 8.83M
Interest expense 1.72M 1.09M 1.22M 2.88M 1.65M
Tax provision -3.03100M -3.25800M -2.36800M -1.70300M -1.32800M
Interest income 0.34M 0.35M 0.28M 0.00400M 0.00300M
Net interest income -1.38100M -0.73400M -0.93100M 2.37M -7.97100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.03100M -3.25800M -2.36800M -1.70300M -1.32800M
Total revenue 4.71M 0.00000M 5.27M 0.00000M 0.00000M
Total operating expenses 18.59M 17.30M 16.67M 13.30M 8.83M
Cost of revenue 1.12M 0.97M 0.53M - 6.41M
Total other income expense net -0.30200M 9.15M -2.38400M 9.53M -7.97100M
Discontinued operations - - - - -
Net income from continuing ops -12.27200M -5.85900M -11.93600M -2.06500M -15.47700M
Net income applicable to common shares - - - -2.06500M -15.47700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Total assets 23.09M 23.58M 30.27M 49.06M 8.82M
Intangible assets 1.62M - - - -
Earning assets - - - - -
Other current assets 0.11M 1.20M - 3.64M 3.56M
Total liab 26.93M 27.08M 36.50M 29.57M 1.17M
Total stockholder equity -3.83500M -3.50500M -6.23300M 19.48M 7.65M
Deferred long term liab - - - - -
Other current liab 10.66M 2.72M - 0.34M 1.20M
Common stock 1.04M 0.93M 0.82M 0.81M 0.47M
Capital stock 1.04M 0.93M 0.82M 0.81M 0.81M
Retained earnings -91.41600M -84.18700M -74.35600M -47.05400M -31.57700M
Other liab - - - 10.10M 12.03M
Good will - - 3.42M 3.42M 3.42M
Other assets - - - - -
Cash 16.89M 14.82M 19.92M 41.11M 3.58M
Cash and equivalents - - - - -
Total current liabilities 26.80M 6.39M 3.28M 2.29M 1.17M
Current deferred revenue - - - - -
Net debt -0.62700M 5.05M -0.38700M -25.65500M -3.44600M
Short term debt 16.14M 2.03M 0.31M 0.21M 0.13M
Short long term debt 15.75M 1.61M - - -
Short long term debt total 16.27M 19.87M 19.53M 15.46M 0.13M
Other stockholder equity 82.40M 79.75M 67.30M 65.72M 38.76M
Property plant equipment - - - 2.74M 0.97M
Total current assets 20.62M 21.87M 24.61M 44.67M 5.21M
Long term investments - - - - -
Net tangible assets - - - 14.70M 16.07M
Short term investments - - - - -
Net receivables 3.73M 5.85M 0.54M 3.19M 3.56M
Long term debt 0.00000M 17.37M 18.48M 7.01M 15.18M
Inventory - 0.53M - - -
Accounts payable 0.61M 1.46M 2.97M 2.09M 1.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 4.14M 2.78M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.47M 1.71M 5.66M 4.39M 3.61M
Capital lease obligations 0.51M 0.89M 1.05M 1.17M 0.27M
Long term debt total - - - - -
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Investments -1.20300M 0.18M 0.08M -1.26400M -0.74100M
Change to liabilities - - - 0.05M 1.05M
Total cashflows from investing activities -1.53900M 0.18M - -1.26400M -0.74100M
Net borrowings -0.45000M 0.00000M - -0.39100M 23.35M
Total cash from financing activities 9.73M 10.39M -0.74600M 46.08M 3.80M
Change to operating activities - - - - -
Net income -12.27200M -9.11700M -14.30400M -16.80500M -6.76800M
Change in cash 2.08M -5.10300M -8.80500M 37.53M -0.98500M
Begin period cash flow 14.82M 19.92M 28.73M 3.58M 4.56M
End period cash flow 16.89M 14.82M 19.92M 41.11M 3.58M
Total cash from operating activities -6.10600M -15.66000M -8.14000M -7.80300M -4.77200M
Issuance of capital stock 11.28M 11.99M 0.17M 0.00000M 24.14M
Depreciation 0.88M 0.97M 0.90M 0.25M 0.04M
Other cashflows from investing activities - 0.35M - 0.00400M 0.00300M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.75M -0.84000M - 0.32M -0.59700M
Sale purchase of stock - - - - 24.14M
Other cashflows from financing activities -0.40100M -1.59900M -0.91200M 21.94M -0.07700M
Change to netincome - - - -9.24000M 6.98M
Capital expenditures 0.01M 0.18M 0.20M 0.74M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.73M -0.71100M 0.94M 0.45M 0.14M
Stock based compensation 1.36M 0.66M 0.73M 0.33M -0.01000M
Other non cash items 4.55M -7.45800M 2.38M 7.97M -0.01100M
Free cash flow -6.12000M -15.83700M -8.34300M -8.54700M -4.79900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SCLP
Scancell Hldgs Plc		 -0.5 2.17% 22.50 - 3.54 26.99 8.89 26.40 -10.4817
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Scancell Hldgs Plc

Bellhouse Building, Oxford, United Kingdom, OX4 4GD

Key Executives

Name Title Year Born
Prof. Lindy Gillian Durrant Ph.D. Founder, CEO, Chief Scientific Officer & Director NA
Dr. Sally Elizabeth Adams Chief Devel. Officer & Director 1961
Mr. Keith Green Director of Fin. & Admin. and Company Sec. NA
Dr. Samantha Paston Ph.D. Head of Translational Research NA
Dr. Adrian Parry Ph.D. Head of Manufacturing NA
Ms. Akua Asare Head of Quality NA
Mr. Fayaz Master Head of Clinical Operations NA
Dr. Phillip John L'Huillier MBA, Ph.D. CEO & Director 1962
Prof. Lindy Gillian Durrant Ph.D. Chief Scientific Officer, Director & Founder 1957
Mr. Sathijeevan Nirmalananthan CFO, Company Secretary & Director 1986

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions